Abstract
Murine monoclonal antibody (Mab) therapy in patients with rheumatoid arthritis (RA) produces an antimouse immunoglobulin response by the recipient. We studied a chimeric (human/mouse) CD7 Mab, in a dose ranging tolerability study in 10 patients with RA. Modest improvements in disease activity occurred with frequent acute adverse effects of malaise, fever and nausea. After treatment, peripheral blood T lymphocyte numbers fell by 50% and CD7 expression fell by 97% for less than 7 days. Our study demonstrates chimeric Mab function in vivo and illustrates the influence of antibody isotype and patient characteristics on adverse effects.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / immunology*
-
Antigens, CD7
-
Antigens, Differentiation, T-Lymphocyte / immunology*
-
Arthritis, Rheumatoid / pathology
-
Arthritis, Rheumatoid / therapy*
-
CD4-CD8 Ratio
-
Dose-Response Relationship, Drug
-
Female
-
Flow Cytometry
-
Humans
-
Immunotherapy
-
Male
-
Middle Aged
-
Recombinant Fusion Proteins / therapeutic use*
-
T-Lymphocytes / immunology
-
T-Lymphocytes / pathology
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, CD7
-
Antigens, Differentiation, T-Lymphocyte
-
Recombinant Fusion Proteins